1. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
- Author
-
Sagawa E, Okubo H, Ando H, Sorin Y, Kanazawa R, Nakadera E, Fukada H, Kokubu S, and Miyazaki A
- Subjects
- Adult, Aged, Aged, 80 and over, Antidiuretic Hormone Receptor Antagonists blood, Ascites complications, Edema complications, Female, Humans, Liver Cirrhosis complications, Liver Diseases complications, Male, Middle Aged, Serum Albumin metabolism, Tolvaptan blood, Treatment Outcome, Antidiuretic Hormone Receptor Antagonists pharmacokinetics, Antidiuretic Hormone Receptor Antagonists therapeutic use, Ascites drug therapy, Ascites metabolism, Edema drug therapy, Edema metabolism, Liver Cirrhosis drug therapy, Liver Cirrhosis metabolism, Liver Diseases drug therapy, Liver Diseases metabolism, Tolvaptan pharmacokinetics, Tolvaptan therapeutic use
- Abstract
To investigate the relationship between the exposure and efficacy of tolvaptan, we measured pharmacokinetics of total drug at 7 days after repeated doses of 3.75 mg/day tolvaptan in 16 patients with hepatic edema. Nine patients (56.3%) were responders, which were defined as those with body weight reduction of >1.5 kg/week. Serum albumin levels were significantly lower in responders than in non-responders (P = 0.031). However, the pharmacokinetics varied greatly among individuals and was not relevant to the clinical response., (Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF